Skip to main content

Table 1 Clinical characteristics and parameters of patients with or without HT

From: Significance of initial, interim and end-of-therapy 18F-FDG PET/CT for predicting transformation risk in follicular lymphoma

  HT Non-HT P-value
Total number of patients 30 189  
Age, years (range) 50.8 ± 6.2 (26–86) 51.2 ± 14.0 (22–71) 0.047
ECOG (0–1/ ≥ 2) 28/2 184/5 0.149
LDH, U/L (mean ± SD) 279 ± 122 231 ± 119 0.136
Bone marrow involvement 11(36.6%) 67(35.4%) 0.510
Area of enlarged lymph nodes (≥ 4) 16(53.3%) 108(52.9%) 0.601
HGB, g/L (mean ± SD) 132.5 ± 21.2 135.4 ± 18.0 0.470
Fibrinogen, g/L (mean ± SD) 3.54 ± 1.23 2.68 ± 0.98 0.001
FLIPI    0.165
 Low (0–1) 5 (9%) 43 (26.7%)
 Intermediate (2) 8 (36.3%) 64 (39.7%)
 High (≥ 3) 9 (40.9%) 54 (33.5%)
FLIPI2    0.059
 Low (0–1) 13 (56.5%) 105 (65.2%)
 Intermediate (2) 6 (26%) 39 (24.2%)
 High (≥ 3) 4 (17.4%) 17 (10.5%)
Pathologic grade    0.000
 Low (1–2) 24 (80%) 67 (35.4%)
 High (3a) 6 (20%) 122 (64.5%)